Merck (MRK) plans to expand its U.S. manufacturing footprint with a $1B plant in Delaware, Jared Hopkins of The Wall Street Journal reports. The facility’s products will include biologic drugs and an easier-to-use version of Keytruda, the company’s cancer drug.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck price target lowered to $100 from $115 at HSBC
- Merck & Co.’s Strategic Resilience and Growth Potential Amidst Macroeconomic Challenges
- Merck’s Earnings Call: Growth Potential and Challenges
- BMO says Keytruda ‘still reigns’ after ivonescimab survival data
- Akeso survival data for ivonescimab misses expectations, STAT says